LV5288A3 - Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1 - Google Patents

Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1

Info

Publication number
LV5288A3
LV5288A3 LV930445A LV930445A LV5288A3 LV 5288 A3 LV5288 A3 LV 5288A3 LV 930445 A LV930445 A LV 930445A LV 930445 A LV930445 A LV 930445A LV 5288 A3 LV5288 A3 LV 5288A3
Authority
LV
Latvia
Prior art keywords
proapolipoprotein
code
sequence
expression vectors
dna sequences
Prior art date
Application number
LV930445A
Other languages
English (en)
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of LV5288A3 publication Critical patent/LV5288A3/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
LV930445A 1987-05-28 1993-06-01 Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1 LV5288A3 (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i
SU884613079A RU2009198C1 (ru) 1987-05-28 1988-12-20 Фрагмент нуклеиновой кислоты, кодирующий человеческий проаполипопротеин а-1

Publications (1)

Publication Number Publication Date
LV5288A3 true LV5288A3 (lv) 1993-10-10

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
LV930445A LV5288A3 (lv) 1987-05-28 1993-06-01 Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1

Country Status (33)

Country Link
US (1) US5059528A (lv)
EP (1) EP0293357B1 (lv)
JP (1) JP2634193B2 (lv)
KR (1) KR970000808B1 (lv)
CN (1) CN1031892C (lv)
AT (1) ATE89006T1 (lv)
AU (1) AU615654B2 (lv)
CA (1) CA1323851C (lv)
CY (1) CY1809A (lv)
CZ (1) CZ283648B6 (lv)
DD (1) DD291093A5 (lv)
DE (1) DE3880739T2 (lv)
DK (1) DK175686B1 (lv)
EG (1) EG19101A (lv)
ES (1) ES2054878T3 (lv)
FI (1) FI100056B (lv)
GB (1) GB8712540D0 (lv)
HK (1) HK137794A (lv)
HU (1) HU204562B (lv)
IE (1) IE62422B1 (lv)
IL (1) IL86480A (lv)
LT (1) LT3600B (lv)
LV (1) LV5288A3 (lv)
NO (1) NO179253C (lv)
NZ (1) NZ224808A (lv)
PL (1) PL158064B1 (lv)
PT (1) PT87562B (lv)
RU (1) RU2009198C1 (lv)
SG (1) SG131594G (lv)
SK (1) SK363888A3 (lv)
SU (1) SU1834904A3 (lv)
UA (1) UA19765A (lv)
ZA (1) ZA883824B (lv)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
IE914102A1 (en) * 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
WO2008104890A2 (en) * 2007-02-28 2008-09-04 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein
EP2352830B1 (en) * 2008-10-03 2019-01-16 CuRNA, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
CA2743139C (en) 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CN104922699B (zh) 2009-03-12 2020-07-24 阿尔尼拉姆医药品有限公司 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
EP3097908A1 (en) 2009-05-05 2016-11-30 Arbutus Biopharma Corporation Lipid compositions
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR101967411B1 (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
RS58275B1 (sr) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoproteinski kompleksi i njihova proizvodnja i upotrebe
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
CN105378085B (zh) * 2013-05-01 2019-02-15 Ionis制药公司 用于调节hbv和ttr表达的组合物和方法
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
US11492616B2 (en) * 2016-10-27 2022-11-08 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
TW201919686A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
EP4221686A2 (en) 2020-10-01 2023-08-09 Abionyx Pharma SA Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
KR20240018430A (ko) 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
AU6522486A (en) 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
AU8273987A (en) * 1986-10-29 1988-05-25 Biotechnology Research Partners Limited Apoai-ciii-aiv, apoaii apob , apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
NZ224808A (en) 1990-01-29
HK137794A (en) 1994-12-16
UA19765A (uk) 1997-12-25
CA1323851C (en) 1993-11-02
CY1809A (en) 1995-10-20
DK289688A (da) 1988-11-29
DK175686B1 (da) 2005-01-17
ZA883824B (en) 1989-02-22
PT87562A (pt) 1989-05-31
AU615654B2 (en) 1991-10-10
PL158064B1 (pl) 1992-07-31
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
FI882456A (fi) 1988-11-29
HUT47153A (en) 1989-01-30
US5059528A (en) 1991-10-22
EP0293357B1 (fr) 1993-05-05
JPS6416589A (en) 1989-01-20
SU1834904A3 (ru) 1993-08-15
RU2009198C1 (ru) 1994-03-15
CN1031892C (zh) 1996-05-29
SK279166B6 (sk) 1998-07-08
JP2634193B2 (ja) 1997-07-23
DE3880739D1 (de) 1993-06-09
DE3880739T2 (de) 1993-08-19
ATE89006T1 (de) 1993-05-15
NO882341D0 (no) 1988-05-27
CZ363888A3 (cs) 1998-02-18
KR880014110A (ko) 1988-12-22
NO882341L (no) 1988-11-29
NO179253B (no) 1996-05-28
IE62422B1 (en) 1995-02-08
HU204562B (en) 1992-01-28
PL272698A1 (en) 1989-03-06
AU1672388A (en) 1988-12-01
IL86480A (en) 1992-08-18
EP0293357A1 (fr) 1988-11-30
NO179253C (no) 1996-09-04
IE881597L (en) 1988-11-28
DD291093A5 (de) 1991-06-20
SK363888A3 (en) 1998-07-08
ES2054878T3 (es) 1994-08-16
SG131594G (en) 1995-01-13
KR970000808B1 (en) 1997-01-20
IL86480A0 (en) 1988-11-15
FI882456A0 (fi) 1988-05-25
FI100056B (fi) 1997-09-15
CZ283648B6 (cs) 1998-05-13
LT3600B (en) 1995-12-27
CN88103118A (zh) 1988-12-14
LTIP828A (en) 1995-02-27
PT87562B (pt) 1992-09-30
EG19101A (en) 1994-09-29

Similar Documents

Publication Publication Date Title
LV5288A3 (lv) Nukleinskabes fragments kurs kode cilveka proapolipoproteinu A-1
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
ES8705467A1 (es) Un procedimiento para producir la proteina apoacuorina
ES2089044T3 (es) Fragmento de dna que codifica un polipeptido que presenta actividad nitrilo hidratasa, un transformante que contiene el fragmento de dna y un proceso para la produccion de amidas utilizando el transformante.
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DE69318716D1 (de) Anti-Katze Immundefiziensvirus (FIV) Impfstoffe
DK0422217T3 (da) Human, rekombinant, placental ribonucleaseinhibitor og fremgangsmåde til produktion
DK595187D0 (da) Minactivin og fremgangsmaade til fremstilling deraf
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
TH5997EX (th) การสร้างโปรอโปดิโปรโปรตีน a-i ของคนโดยการแสดงออกของรหัสพันธุกรรม